Veterinary Medicine and Research.
Address Reagent, Biomarker, and Therapeutic Gaps in Veterinary Medicine and Research.
As human and animal populations continue to grow worldwide, so do the demands in products that sustain and manage human and animal welfare. In the past few decades, there have been a number of important advances in the veterinary field; however, information gaps are still very much present due to the limited understanding of many species’ immune systems. This is largely due to the shortage of whole genome sequencing data and the lack of immunological reagents for many species.
Next generation protein sequencing (NGPS) allows for: direct access to the protein to fill in species-specific genetic data gaps; characterization of complex zoonotic bacterial, viral, prion antigens and their associated post-translational modifications; diagnostics development by identifying custom anti-drug and anti-hapten antibodies; and development of antibody therapeutics.
Services for Veterinary Medicine and Research.
We support research and development efforts in the animal health industries. Contact us to discover how we can help with your veterinary medicine and research application.
De Novo Sequencing
Sequence antibodies that bind to complex zoonotic protein targets (eg. prions) to easily develop diagnostic, purification and characterization tools.
Explore Antibody Sequencing Services
Antibody Discovery Services
Sequence and identify mAbs from the serum of companion and livestock animals for therapeutics development.
Explore Antibody Discovery Services
HDX-MS Epitope Mapping
Characterize prion protein structures under misfolding-promoting conditions, and other antigenic epitopes of interest.
Explore Epitope Mapping Services
ADA Reagent Development
Derive custom anti-drug antibody (ADA) control reagents from circulating pAbs without culling the producer animal for improved ADA assays.
Explore Antibody Discovery Services
Antibody Characterization
Our deep expertise working with antibodies, high throughput mass spectrometry and advanced software will give you critical insights in your antibody.
Explore Antibody Characterization Services
Application Publications.
Best Hosts for Antibody Discovery and Generation
Written by: Genya Gorshtein, MSc Published: August 26, 2024 Contents Introduction Advantages of [...]
Exploring the Sheep (Ovis aries) Immunoglobulin Repertoire by Next Generation Sequencing
By conducting an in-depth analysis of non-antigen immunized sheep Ig repertoires via NGS, this data provides further insight into the adaptive immunity of sheep and lays a foundation for future work on immunogenetics and ovine antibody drug development.
Nanobody Lead Optimization with Epitope Mapping and Binning
In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can [...]
Selecting Specific Monoclonal Antibodies by SPR – Alpaca Antibody Showdown
In this SPR webinar, you will learn: How SPR works and its [...]
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Talk to Our Scientists.
We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics